Skip to main content

Cell-based Technologies & Therapeutics Global Developer Expands its Immuno-Oncology (mRNA)-based Platform. IND Application on the Horizon for this rising NASDAQ Company: Avalon Globocare Corp (NASDAQ:

By: Get News
Cell-based Technologies & Therapeutics Global Developer Expands its Immuno-Oncology (mRNA)-based Platform. IND Application on the Horizon for this rising NASDAQ Company: Avalon Globocare Corp (NASDAQ:

Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage CellTech bio-developer involved in advanced oncology therapies. Their CAR-T technology will remove cells from a cancer patient’s body, modify them and introduce the modified cancer fighting cells back into the patient.

AVCO is focused on advancing their immune effector cell therapies, including CAR-T and CAR-NK, their S-layer coated emulsome technology (SLET), their exosome-based regenerative therapeutics (ACTEX™), as well as their liquid biopsy diagnostic and drug delivery platforms. The AVCO website is an excellent source of info on their technology.

AVCO’s lead candidate, AVA-011, combines Avalon’s FLASH-CAR™ technology with an innovative messenger ribonucleic acid (mRNA)-based technology platform, and is currently at an IND-enabling stage. Avalon is on track to initiate AVA-011 first-in-human clinical trial by mid-2022. The company anticipates their technology can modify cells quicker (days not weeks) and cheaper than other CAR-T therapies.

Dr. David Jin, President and CEO has said, “As we head further into 2022, we believe we have a number of important upcoming milestones that have the potential to drive significant value for our shareholders.”

AVCO statistics:

FYE is 12-31 – Outstanding shares 88.4M – Float 33.3M shares – Insider ownership is 62.9% – 52-week high is $1.57/share – Market cap $59M – Revenues of $1.45M

AVCO posted revenues of $1.45M as of their last reporting for Q. This Q was their strongest performance in 2021 coming in at $486K revenues. Expect AVCO to update their earning report in the next few weeks.

Recent developments at AVCO:

In late December, the company’s Chairman, Daniel Lu, converted $3.0 million of debt owed to him under the company’s Line of Credit into 2.4 million shares of the Company’s common stock at $1.25 per share.

The conversion price was at a 45% premium to the share price at the time. That move indicates Mr. Lu’s confidence in the company. Last year the company announced that it planned to acquire SenlangBio, a company that had initiated a first-in-human clinical trial evaluating anti-EphA2 chimeric antigen receptor (CAR) T-cell therapy for recurrent glioblastoma. The all-stock transaction was going to be for 81M AVCO common shares, a significant dilution for shareholders. 

The company announced it had cancelled the planned acquisition citing the significant dilution to shareholders. Good news for investors today as the company value has already reflected the dilution. Let’s compare AVCO with other NASDAQ development stage companies in the oncology sector that are absent revenues: BriaCell Therapeutics Corp. (BCTX) Market Value $137M ALX Oncology Holdings Inc. (ALXO) Market Value $812M Avalon GloboCare Corp. (AVCO) Market Value $59M PDS Biotechnology Corporation (PDSB) Market Value $189M

** Important to note: AVCO is revenue positive ** AVCO Development Highlights: Avalon entered a new collaboration with University of Pittsburgh Medical Center (UPMC) to develop new cancer immunotherapy approaches and streamline manufacturing processes to bring these powerful treatments to cancer patients with a rapid bio-manufacturing time (1-2 days instead of weeks). Avalon’s lead candidate, AVA-011, combines Avalon’s FLASH-CAR™ technology with an innovative messenger ribonucleic acid (mRNA)-based technology platform, and is currently at an IND-enabling stage. Avalon is on track to initiate AVA-011 first-in-human clinical trial by mid-2022. Avalon has co-developed and jointly filed a patent with BOKU on a novel platform of S-layer coated emulsome technology (SLET) for next-generation, targeted drug delivery and cellular immunotherapy applications.

The Company believes this novel SLET platform will help accelerate the development of Avalon’s mRNA-based Flash-CAR™ and other cellular therapy programs. Targeted delivery of mRNA into immune effector cells using SLET can potentially open the door to new generation of cancer immunotherapy and other applications including targeted drug delivery and therapeutics, vaccine development, in vitro diagnostics, and cellular medicines.

The new CAR-NK therapies in development are intended to build upon and complement AVA-011, Avalon’s lead CAR-T candidate, part of the Company’s proprietary mRNA-based FLASH-CAR™ platform. AVA-011 is currently at the IND-enabling, process development stage, which is expected to produce clinical-grade CAR-T cells for an upcoming clinical trial in patients with hematological malignancies. The platform uses next generation CAR technology to modify patients’ T or universal-donor NK cells using a ribonucleic acid (RNA)-based platform rather than a viral vector, allowing for more rapid and lower-cost bio-manufacturing of the cell therapy products. To further strengthen its CAR-NK development capabilities, Avalon has appointed Dr. Dongfang Liu to its Scientific and Clinical Advisory Board. Dr. Liu is currently an Associate Professor and Director of Immunoassay Development Program at the Department of Pathology, Immunology and Laboratory Medicine at The Rutgers University New Jersey Medical School. Dr. Liu’s research expertise is focused on the immunobiology of NK and CAR-NK, with more than 20 years of experience in NK cell research.

About Avalon GloboCare Corp: 

AVCO is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics.


CAP/FrontPageStocks/ (CA) is a third-party publisher and news dissemination service provider. CAP/FPS/CA is NOT affiliated in any manner with any company mentioned herein. CAP/FPS/CA is a news dissemination solutions provider and is NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. CAP/FPS/CA’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. 

All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. CAP/FPS/ CA is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. CAP/FPS/CA has been compensated $500 by a third party for dissemination of this article.

Disclaimer/Safe Harbor:

These news releases and postings may contain forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Media Contact
Company Name: Avalon GloboCare Corp
Contact Person: David K. Jin, President & CEO
Email: Send Email
Phone: (732) 780-4400
Address:4400 ROUTE 9 SOUTH SUITE 3100
City: Freehold
State: New Jersey, 07728
Country: United States

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.